Difference between revisions of "Team:NJU-China/HP"
1582149823 (Talk | contribs) |
1582149823 (Talk | contribs) |
||
| Line 117: | Line 117: | ||
<div class="overlay"></div> | <div class="overlay"></div> | ||
| − | + | <!-- Sidebar --> | |
<nav class="navbar navbar-inverse navbar-fixed-top" id="sidebar-wrapper" role="navigation"> | <nav class="navbar navbar-inverse navbar-fixed-top" id="sidebar-wrapper" role="navigation"> | ||
<ul class="nav sidebar-nav"> | <ul class="nav sidebar-nav"> | ||
| Line 141: | Line 141: | ||
<li class="dropdown-header"><a href="https://2017.igem.org/Team:NJU-China/Results/Conclusions">Results</a></li> | <li class="dropdown-header"><a href="https://2017.igem.org/Team:NJU-China/Results/Conclusions">Results</a></li> | ||
<li><a href="https://2017.igem.org/Team:NJU-China/Results/Conclusions">Conclusions</a></li> | <li><a href="https://2017.igem.org/Team:NJU-China/Results/Conclusions">Conclusions</a></li> | ||
| − | |||
<li><a href="https://2017.igem.org/Team:NJU-China/Safety">Safety</a></li> | <li><a href="https://2017.igem.org/Team:NJU-China/Safety">Safety</a></li> | ||
| − | |||
</ul> | </ul> | ||
</li> | </li> | ||
<li> | <li> | ||
<a href="https://2017.igem.org/Team:NJU-China/Basic_Part"><i class="fa fa-fw fa-plus"></i> Parts </a> | <a href="https://2017.igem.org/Team:NJU-China/Basic_Part"><i class="fa fa-fw fa-plus"></i> Parts </a> | ||
| − | </li> | + | </li> |
| + | <li> | ||
| + | <a href="https://2017.igem.org/Team:NJU-China/Model"><i class="fa fa-fw fa-plus"></i> Model </a> | ||
| + | </li> | ||
| + | <li class="dropdown"> | ||
<a href="https://2017.igem.org/Team:NJU-China/Notebook" class="dropdown-toggle" data-toggle="dropdown"><i class="fa fa-fw fa-plus"></i> Notebook <span class="caret"></span></a> | <a href="https://2017.igem.org/Team:NJU-China/Notebook" class="dropdown-toggle" data-toggle="dropdown"><i class="fa fa-fw fa-plus"></i> Notebook <span class="caret"></span></a> | ||
<ul class="dropdown-menu" role="menu"> | <ul class="dropdown-menu" role="menu"> | ||
<li class="dropdown-header"><a href="https://2017.igem.org/Team:NJU-China/Notebook">Notebook</a></li> | <li class="dropdown-header"><a href="https://2017.igem.org/Team:NJU-China/Notebook">Notebook</a></li> | ||
| − | |||
<li><a href="https://2017.igem.org/Team:NJU-China/Protocol">Protocol</a></li> | <li><a href="https://2017.igem.org/Team:NJU-China/Protocol">Protocol</a></li> | ||
| − | <li><a href="https://2017.igem.org/Team:NJU-China/ | + | <li><a href="https://2017.igem.org/Team:NJU-China/Notebook">Calendar</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
| Line 163: | Line 164: | ||
<li><a href="https://2017.igem.org/Team:NJU-China/HP/Silver">Silver HP</a></li> | <li><a href="https://2017.igem.org/Team:NJU-China/HP/Silver">Silver HP</a></li> | ||
<li><a href="https://2017.igem.org/Team:NJU-China/HP/Gold_Integrated">Intergrated and Gold</a></li> | <li><a href="https://2017.igem.org/Team:NJU-China/HP/Gold_Integrated">Intergrated and Gold</a></li> | ||
| − | |||
</ul> | </ul> | ||
</li> | </li> | ||
| Line 177: | Line 177: | ||
</nav> | </nav> | ||
<!-- /#sidebar-wrapper --> | <!-- /#sidebar-wrapper --> | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
<!-- Page Content --> | <!-- Page Content --> | ||
Revision as of 13:01, 1 November 2017
Human Practice
Our human practice involves social activity and public engagement. We work on promotion of the knowledge for targeted therapy and survey on people’s attitude towards all the weight loss program which includes our work. Besides, we get in touch with doctor and patients to establish contact with clinical treatment.
Obesity has become increasingly disturbing and common these years since it gets in the way of people pursuing beauty and health. To improve our project ulteriorly and help people practically, we worked on the publicity of targeted therapeutics and the surveys of people’s attitudes towards various weight-losing methods or efforts. Additionally, we communicated with doctors and patients in person to acquire more information about clinical treatments, hoping to know more about the feasibility of our targeted therapeutics.
